Shushan Hovsepyan: Elective discontinuation of Larotrectinib in Pediatric TRK Fusion Sarcomas by Leo Mascarenhas
Shushan Hovsepyan, Editor-in-Chief of OncoDaily Medical Journal, shared a post on LinkedIn about a recent paper by Leo Mascarenhas et al. published in Journal of Clinical Oncology:
“The first study exploring elective discontinuation of Larotrectinib in Pediatric TRK Fusion Sarcomas led by Prof. Leo Mascarenhas.
This study published in Journal of Clinical Oncology investigated the elective discontinuation of VITRAKVI (larotrectinib) HCP in pediatric TRK fusion sarcomas, aiming to evaluate the feasibility and clinical outcomes of treatment interruption in patients who had previously demonstrated clinical benefit.
Patient Population: 91 pediatric patients, median age: 2.3 years
- 49 infantile fibrosarcoma (IFS)
- 41 other soft tissue sarcomas (STS)
- 1 bone sarcoma
Key findings:
- 87% ORR across all patients.
- 52% complete response (CR).
- 35% partial response (PR).
- 47 patients entered the wait-and-see cohort, with 34% experiencing disease progression after elective discontinuation.
Of the 16 patients who experienced progression and resumed treatment:
- 94% regained disease control.
- 69% showed an objective response (including 5 CR and 6 PR).
Key Takeaways:
- Larotrectinib shows durable efficacy in pediatric TRK fusion sarcomas, with an 87% overall response rate.
- Elective treatment discontinuation is feasible for certain patients, with 94% of those who resumed treatment after progression achieving disease control.
- The approach allows for reduced treatment exposure without compromising clinical outcomes, demonstrating the potential for personalized treatment strategies in pediatric oncology.
Clinical Trials: SCOUT (NCT02637687), NAVIGATE (NCT02576431).”
Authors: Leo Mascarenhas, Steven DuBois, Catherine Albert, Cornelis van Tilburg, Theodore Laetsch et al.
More posts featuring Shushan Hovsepyan.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023